Skip to content
My WebMD Sign In, Sign Up

Heartburn/GERD Health Center

Font Size
A
A
A

FDA OKs New GERD Drug Kapidex

Once-Daily Formula Approved to Treat GERD and Erosive Esophagitis
By
WebMD Health News
Reviewed by Louise Chang, MD

new_gerd_drug_approved.jpg

Feb. 6, 2009 -- The FDA has approved Kapidex delayed-release capsules as a once-daily treatment for gastroesophageal reflux disease (GERD) and for erosive esophagitis, which is GERD-related damage to the esophagus.

Kapidex, which is taken orally, belongs to a class of drugs called proton pump inhibitors. It's the first proton pump inhibitor with a dual delayed release formulation, which provides two separate releases of medication, according to Takeda Pharmaceutical Company, which makes Kapidex.

In a news release, Takeda says that the FDA approved Kapidex based on global studies of about 6,000 GERD patients, some of whom had erosive esophagitis. In those studies, Kapidex trumped a placebo at treating heartburn. Among erosive esophagitis patients studied, those taking Kapidex also showed high healing rates of erosive esophagitis that were comparable to erosive esophagitis healing rates among patients taking Prevacid, another proton pump inhibitor made by Takeda.

Takeda reports that the most commonly reported adverse reactions with Kapidex included diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Today on WebMD

Heartburn illustration
Slideshow
Heartburn Control Assess Your Symptoms
Assessment
 
heartburn foods
Slideshow
Nighttime Heartburn
Article
 
digestive health
Slideshow
Heartburn or Heart Attack
Video
 
heartburn
Article
Top 10 Heartburn Foods
Article
 
Is it Heartburn or Gerd
Video
digestive myths
Slideshow
 
Extreme Eats
Slideshow
graphic of esophageal area
Article